<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-121255</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Proteinase activity in Candida albicans strains isolated from the oral cavity of immunocompromised patients, with oral candidiasis and in healthy subjects</dc:title>
<dc:description xml:lang="en">Background. Candida albicans has a variety of virulence factors, including secreted aspartyl proteases, which are determinant factors in the pathogenesis of this yeast in immunocompromised patients. Aims. Proteinase activity was identified in C. albicans strains isolated from the oral cavity of immunocompromised patients with cancer, diabetes and HIV+, with oral candidiasis and in healthy subjects. Methods. Two hundred and fifty C. albicans strains were analyzed, distributed in 5 different groups: patients with cancer, diabetes, HIV+, with oral candidiasis and healthy subjects. Results. Proteolytic activity was identified in 46% of the strains from cancer patients, 54% from HIV+ patients, 60% from diabetics, 70% from oral candidiasis patients, and 42% from healthy subjects. Activity was higher in strains from immunocompromised and oral candidiasis patients than in healthy subjects. Differences were observed between the candidiasis-healthy, candidiasis-HIV+, and diabetic-healthy groups. No differences were observed between the oral candidiasis, diabetes and cancer patients, between the diabetes and HIV+ patients, or between the cancer patients, HIV+ patients and healthy subjects. Conclusions. The present results suggest that although secreted aspartyl proteases are important in the pathogenesis of C. albicans, their activity depends on host conditions (AU)</dc:description>
<dc:creator>Rueda-Gordillo, Florencio</dc:creator>
<dc:creator>Hernández-Solís, Sandra E</dc:creator>
<dc:creator>Rojas-Herrera, Rafael A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Antecedentes. Candida albicans posee una variedad de factores de virulencia, entre los que se encuentran las enzimas aspartil proteinasas, que constituyen un factor determinante en la patogénesis de esta levadura en pacientes inmunodeprimidos. Objetivos. El propósito de este estudio fue determinar la actividad de la proteinasa de cepas de C. albicans aisladas de la cavidad oral de pacientes inmunodeprimidos con cáncer, diabéticos y seropositivos a VIH, con candidiasis oral y sujetos sanos. Métodos. Se analizaron 250 cepas de C. albicans distribuidas en 5 grupos diferentes: pacientes con cáncer, diabéticos, seropositivos a VIH, con candidiasis oral y sujetos sanos. Resultados. El 46% de las cepas provenientes de pacientes con cáncer, el 54% de VIH, el 60% de diabéticos, el 70% de candidiasis oral y el 42% de sujetos sanos presentaron actividad proteolítica. Las cepas de los pacientes inmunodeprimidos y con candidiasis oral presentaron una mayor actividad proteolítica que las de los sujetos sanos. Se encontró diferencia estadísticamente significativa entre los grupos de candidiasis-sanos, candidiasis-VIH y diabéticos-sanos. No se encontraron diferencias estadísticamente significativas entre las cepas de los pacientes con candidasis oral, diabéticos y con cáncer; tampoco entre los pacientes diabéticos y con VIH, ni entre los pacientes con cáncer, VIH y sujetos sanos. Conclusiones. Con estos hallazgos se puede inferir que a pesar de que las enzimas aspartil proteinasas juegan un papel importante en la patogénesis de C. albicans, su actividad depende de las condiciones del huésped (AU)</dc:description>
<dc:source>Rev Iberoam Micol;31(2): 137-140, abr.-jun. 2014.</dc:source>
<dc:identifier>ibc-121255</dc:identifier>
<dc:title xml:lang="es">Actividad de la proteinasa en cepas de Candida albicans aisladas de la cavidad oral de pacientes inmunodeprimidos, con candidiasis oral y sujetos sanos</dc:title>
<dc:subject>^d2212^s22057</dc:subject>
<dc:subject>^d37540^s22002</dc:subject>
<dc:subject>^d37540^s22001</dc:subject>
<dc:subject>^d2212^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23555^s22048</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d15176^s22021</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2212^s22016</dc:subject>
<dc:subject>^d2212^s22038</dc:subject>
<dc:subject>^d9247^s22046</dc:subject>
<dc:subject>^d10642^s22044</dc:subject>
<dc:subject>^d2208^s22052</dc:subject>
<dc:subject>^d9247^s22032</dc:subject>
<dc:subject>^d23555^s22045</dc:subject>
<dc:subject>^d10642^s22021</dc:subject>
<dc:subject>^d2208^s22021</dc:subject>
<dc:subject>^d2208^s22001</dc:subject>
<dc:subject>^d10642</dc:subject>
<dc:subject>^d9247^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201406</dc:date>
</metadata>
</record>
</ibecs-document>
